Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis
- PMID: 24769197
- PMCID: PMC4065856
- DOI: 10.1016/j.ejmg.2014.04.005
Clinical utility of whole-exome sequencing in rare diseases: Galactosialidosis
Abstract
Rare genetic disorders can go undiagnosed for years as the entire spectrum of phenotypic variation is not well characterized given the reduced number of patients reported in the literature and the low frequency at which these occur. Moreover, the current paradigm for clinical diagnostics defines disease diagnosis by a specified spectrum of phenotypic findings; when such parameters are either missing, or other findings not usually observed are seen, the phenotype driven approach to diagnosis may result in a specific etiological diagnosis not even being considered within the differential diagnosis. The novel implementation of genomic sequencing approaches to investigate rare genetic disorders is allowing not only the discovery of new genes, but also the phenotypic expansion of known Mendelian genetic disorders. Here we report the detailed clinical assessment of a patient with a rare genetic disorder with undefined molecular diagnosis. We applied whole-exome sequencing to this patient and unaffected parents in order to identify the molecular cause of her disorder. We identified compound heterozygous mutations in the CTSA gene, responsible for causing galactosialidosis; the molecular diagnosis was further confirmed by biochemical studies. This report expands on the clinical spectrum of this rare lysosomal disorder and exemplifies how genomic approaches are further elucidating the characterization and understanding of genetic diseases.
Keywords: Exome sequencing; Galactosialidosis; Protective protein cathepsin A.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
Figures
References
-
- Bainbridge M, Hu H, Muzny D, Musante L, Lupski J, Graham B, Chen W, Gripp K, Jenny K, Wienker T, Yang Y, Sutton V, Gibbs R, Ropers H. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Medicine. 2013;5(2):11. - PMC - PubMed
-
- Bainbridge MN, Wiszniewski W, Murdock DR, Friedman J, Gonzaga-Jauregui C, Newsham I, Reid JG, Fink JK, Morgan MB, Gingras M-C, Muzny DM, Hoang LD, Yousaf S, Lupski JR, Gibbs RA. Whole-Genome Sequencing for Optimized Patient Management. Science Translational Medicine. 2011;3(87):87re83. - PMC - PubMed
-
- Dixon-Salazar TJ, Silhavy JL, Udpa N, Schroth J, Bielas S, Schaffer AE, Olvera J, Bafna V, Zaki MS, Abdel-Salam GH, Mansour LA, Selim L, Abdel-Hadi S, Marzouki N, Ben-Omran T, Al-Saana NA, Sonmez FMj, Celep F, Azam M, Hill KJ, Collazo A, Fenstermaker AG, Novarino G, Akizu N, Garimella KV, Sougnez C, Russ C, Gabriel SB, Gleeson JG. Exome Sequencing Can Improve Diagnosis and Alter Patient Management. Science Translational Medicine. 2012;4(138):138ra178. - PMC - PubMed
-
- d’Azzo A, Andria G, Bonten E, Annunziata I. Valle D, editor. [Updated March 28, 2011];Online Metabolic and Molecular Bases of Inherited Disease. Chapter 152: Galactosialidosis. Published January 2006. DOI: 10.1036/ommbid.183.
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous
